Terms: = Prostate cancer AND TRIM27, DASS-46L4_6, RFP, 5987, ENSG00000234495, RNF76 AND Clinical Outcome
326 results:
1. Adrenal incidentalomas, cortisol secretion and cancer: is there a real crosstalk?
Herrera-Martínez AD; Román ÁR; Corrales EP; Idrobo C; Ramírez PP; Rojas PM; Lázaro CR; Araujo-Castro M
Front Endocrinol (Lausanne); 2023; 14():1335202. PubMed ID: 38264281
[TBL] [Abstract] [Full Text] [Related]
2. Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant prostate cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy.
van der Zande K; Tutuhatunewa-Louhanepessy RD; Hamberg P; Ras S; de Feijter JM; Dezentjé VO; Broeks A; Cornelissen S; Beeker A; van der Noort V; Zwart W; Bergman AM
Clin Genitourin Cancer; 2024 Apr; 22(2):445-453.e1. PubMed ID: 38246830
[TBL] [Abstract] [Full Text] [Related]
3. Early response monitoring during [
Neubauer MC; Nicolas GP; Bauman A; Fani M; Nitzsche E; Afshar-Oromieh A; Forrer F; Rentsch C; Stenner F; Templeton A; Schäfer N; Wild D; Chirindel A;
Eur J Nucl Med Mol Imaging; 2024 Mar; 51(4):1185-1193. PubMed ID: 38038755
[TBL] [Abstract] [Full Text] [Related]
4. Whole exome germline sequencing in early-onset prostate cancer patients: Genomic findings and clinical outcomes.
Siegelmann-Danieli N; Neiman V; Bareket-Samish A; Berger R; Peretz A; Alapi H; Tsur E; Patalon T; Beller D; Rimler G; Chodick G; Shohat M
Prostate; 2024 Jan; 84(1):39-46. PubMed ID: 37842866
[TBL] [Abstract] [Full Text] [Related]
5.
de Jong AC; Segbers M; Ling SW; Graven LH; Mehra N; Hamberg P; Brabander T; de Wit R; van der Veldt AAM
J Nucl Med; 2023 Oct; 64(10):1556-1562. PubMed ID: 37536738
[TBL] [Abstract] [Full Text] [Related]
6. Early biochemical and radiographic response after one cycle of [
Cytawa W; Hendel R; Tomasik B; Weinzierl FX; Bley T; Jassem J; Schirbel A; Buck AK; Bundschuh RA; Hartrampf PE; Werner RA; Lapa C
Eur J Nucl Med Mol Imaging; 2023 Oct; 50(12):3765-3776. PubMed ID: 37474735
[TBL] [Abstract] [Full Text] [Related]
7. A Multi-institution Study on the Association of Virtual Reality Skills with Continence Recovery after Robot-assisted Radical prostatectomy.
Chu TN; Wong EY; Ma R; Yang CH; Dalieh IS; Hui A; Gomez O; Cen S; Ghazi A; Miles BJ; Lau C; Davis JW; Goldenberg MG; Hung AJ
Eur Urol Focus; 2023 Nov; 9(6):1044-1051. PubMed ID: 37277274
[TBL] [Abstract] [Full Text] [Related]
8. PSMA-heterogeneity in metastatic castration-resistant prostate cancer: Circulating tumor cells, metastatic tumor burden, and response to targeted radioligand therapy.
Derlin T; Riethdorf S; Schumacher U; Lafos M; Peine S; Coith C; Ross TL; Pantel K; Bengel FM
Prostate; 2023 Aug; 83(11):1076-1088. PubMed ID: 37147881
[TBL] [Abstract] [Full Text] [Related]
9. Randomized Phase II Cabazitaxel Dose Individualization and Neutropenia Prevention Trial in Patients with Metastatic Castration-Resistant prostate cancer.
Omlin A; Cathomas R; von Amsberg G; Reuter C; Feyerabend S; Loidl W; Boegemann M; Lorch A; Heidenreich A; Tsaur I; Larcher-Senn J; Buck SAJ; Mathijssen RHJ; Jaehde U; Gillessen S; Joerger M
Clin Cancer Res; 2023 May; 29(10):1887-1893. PubMed ID: 36917691
[TBL] [Abstract] [Full Text] [Related]
10. Impact of human telomerase reverse transcriptase peptide vaccine combined with androgen deprivation therapy and radiotherapy in de novo metastatic prostate cancer: Long-term clinical monitoring.
Lilleby W; Seierstad T; Inderberg EM; Hole KH
Int J Cancer; 2023 May; 152(10):2166-2173. PubMed ID: 36715014
[TBL] [Abstract] [Full Text] [Related]
11. Synthesis and evaluation of 7-(3-aminopropyloxy)-substituted flavone analogue as a topoisomerase IIα catalytic inhibitor and its sensitizing effect to enzalutamide in castration-resistant prostate cancer cells.
Jeon KH; Park S; Shin JH; Jung AR; Hwang SY; Seo SH; Jo H; Na Y; Kwon Y
Eur J Med Chem; 2023 Jan; 246():114999. PubMed ID: 36493620
[TBL] [Abstract] [Full Text] [Related]
12. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.
Kafka M; Burtscher T; Fritz J; Schmitz M; Bektic J; Ladurner M; Horninger W; Heidegger I
World J Urol; 2023 Aug; 41(8):2043-2050. PubMed ID: 36287244
[TBL] [Abstract] [Full Text] [Related]
13. Accumulation of copy number alterations and clinical progression across advanced prostate cancer.
Grist E; Friedrich S; Brawley C; Mendes L; Parry M; Ali A; Haran A; Hoyle A; Gilson C; Lall S; Zakka L; Bautista C; Landless A; Nowakowska K; Wingate A; Wetterskog D; Hasan AMM; Akato NB; Richmond M; Ishaq S; Matthews N; Hamid AA; Sweeney CJ; Sydes MR; Berney DM; Lise S; ; Parmar MKB; Clarke NW; James ND; Cremaschi P; Brown LC; Attard G
Genome Med; 2022 Sep; 14(1):102. PubMed ID: 36059000
[TBL] [Abstract] [Full Text] [Related]
14. Loss of KLK4::KLKP1 pseudogene expression by RNA chromogenic in-situ hybridization is associated with PTEN loss and increased risk of biochemical recurrence in a cohort of middle eastern men with prostate cancer.
Bakker A; Slack JC; Palanisamy N; Carskadon S; Ghosh S; Khalifeh I; Bismar TA
J Cancer Res Clin Oncol; 2023 Jul; 149(7):3721-3728. PubMed ID: 35982181
[TBL] [Abstract] [Full Text] [Related]
15. Non-canonical EphA2 activation underpins PTEN-mediated metastatic migration and poor clinical outcome in prostate cancer.
Sachdeva A; Hart CA; Kim K; Tawadros T; Oliveira P; Shanks J; Brown M; Clarke N
Br J Cancer; 2022 Oct; 127(7):1254-1262. PubMed ID: 35869144
[TBL] [Abstract] [Full Text] [Related]
16. Cranial Radiotherapy for prostate cancer Patients With Brain Metastases Inaccessible to Stereotactic Radiotherapy.
Schröder C; Windisch P; Lütscher J; Zwahlen DR; Förster R
In Vivo; 2022; 36(4):1841-1846. PubMed ID: 35738629
[TBL] [Abstract] [Full Text] [Related]
17. High eEF1A1 Protein Levels Mark Aggressive prostate cancers and the In Vitro Targeting of eEF1A1 Reveals the eEF1A1-actin Complex as a New Potential Target for Therapy.
Bosutti A; Dapas B; Grassi G; Bussani R; Zanconati F; Giudici F; Bottin C; Pavan N; Trombetta C; Scaggiante B
Int J Mol Sci; 2022 Apr; 23(8):. PubMed ID: 35456960
[TBL] [Abstract] [Full Text] [Related]
18. Large and small cribriform architecture have similar adverse clinical outcome on prostate cancer biopsies.
Rijstenberg LL; Hansum T; Kweldam CF; Kümmerlin IP; Remmers S; Roobol MJ; van Leenders GJLH
Histopathology; 2022 Jun; 80(7):1041-1049. PubMed ID: 35384019
[TBL] [Abstract] [Full Text] [Related]
19. clinical outcome and Prognostic Variables of Second-line Therapy for Patients With Castration-resistant prostate cancer After Failure of First-line Androgen Receptor Axis-targeted Therapy.
Fujiwara M; Fujiwara R; Oguchi T; Komai Y; Numao N; Yamamoto S; Yonese J; Yuasa T
Anticancer Res; 2022 Apr; 42(4):2123-2130. PubMed ID: 35347036
[TBL] [Abstract] [Full Text] [Related]
20. IL-6 and IL-8 cytokines are associated with elevated prostate-specific antigen levels among patients with adenocarcinoma of the prostate at the Uganda cancer Institute.
Katongole P; Sande OJ; Nabweyambo S; Joloba M; Kajumbula H; Kalungi S; Reynolds SJ; Ssebambulidde K; Atuheirwe M; Orem J; Niyonzima N
Future Oncol; 2022 Feb; 18(6):661-667. PubMed ID: 34881637
[No Abstract] [Full Text] [Related]
[Next]
